Related ATHXMorning Market GainersWhy Investors Are Watching Athersys Ahead Of Stem Cell DataIn a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here’s a rundown of what they had to say.Athersys, Inc. (NASDAQ: ATHX)Analysts believe that Athersys may have found a “sweet spot” for stroke treatment timing, as […]
Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]
Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]
Related ACHNAfter-Hours Movers Led By Bob Evans, Bazaarvoice And Smith & Wesson On TuesdayTop 5 Biotech Stocks That The Smart Money Doesn’t LikeAchillion Pharma updates guidance after Q4 results(Seeking Alpha)Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at […]
REUTERS/Shannon StapletonHenry Kravis of Kohlberg Kravis Roberts & Co.Kohlberg Kravis Roberts & Co. (KKR) is out with its outlook for 2014.
“We believe that we are now entering the global synchronous phase of a long but bumpy recovery process that started in 2009,” wrote Henry McVey, KKR’s Head of Global Macro & Asset Allocation.”However, unlike many other synchronized global recoveries, developed […]
